103 related articles for article (PubMed ID: 9180856)
1. [First-line chemotherapy in operable breast neoplasms: results of 3 protocols].
Cure H; Charrier S; Ferrière JP; Van Praagh I; Assier I; Feillel V; De Latour M; Bay JO; Achard JL; Dauplat J; Chollet P
Bull Cancer; 1997 Jan; 84(1):31-4. PubMed ID: 9180856
[TBL] [Abstract][Full Text] [Related]
2. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
Boccardo F; Amadori D; Guglielmini P; Sismondi P; Farris A; Agostara B; Gambi A; Catalano G; Faedi M; Rubagotti A
Oncology; 2010; 78(3-4):274-81. PubMed ID: 20530973
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pathological response to primary chemotherapy in operable breast cancer.
Chollet P; Charrier S; Brain E; Curé H; van Praagh I; Feillel V; de Latour M; Dauplat J; Misset JL; Ferrière JP
Eur J Cancer; 1997 May; 33(6):862-6. PubMed ID: 9291806
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer.
Van Praagh I; Cure H; Leduc B; Charrier S; Le Bouedec G; Achard JL; Ferriere JP; Feillel V; De Latour M; Dauplat J; Chollet P
Oncologist; 2002; 7(5):418-23. PubMed ID: 12401904
[TBL] [Abstract][Full Text] [Related]
5. Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.
Amat S; Mouret-Reynier MA; Penault-Llorca F; Leheurteur M; Delva R; Coudert B; Leduc B; Dauplat J; Curé H; Chollet P
Clin Breast Cancer; 2006 Aug; 7(3):262-9. PubMed ID: 16942644
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy in 126 operable breast cancers.
Bélembaogo E; Feillel V; Chollet P; Curé H; Verrelle P; Kwiatkowski F; Achard JL; Le Bouëdec G; Chassagne J; Bignon YJ
Eur J Cancer; 1992; 28A(4-5):896-900. PubMed ID: 1524919
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).
Chua S; Smith IE; A'Hern RP; Coombes GA; Hickish TF; Robinson AC; Laing RW; O'Brien ME; Ebbs SR; Hong A; Wardley A; Mughal T; Verrill M; Dubois D; Bliss JM;
Ann Oncol; 2005 Sep; 16(9):1435-41. PubMed ID: 15946977
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
11. [A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer].
Ferrero JM; Namer M; Dufour JF; Largillier R; Creisson A; Teissier E; Machiavello JC; Lallement M; Monticelli J; Abbes M
Bull Cancer; 1997 Jan; 84(1):10-6. PubMed ID: 9180853
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
Chow LW; Day W; Ng KC
Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
[TBL] [Abstract][Full Text] [Related]
16. [A study of the combination of vinorelbine and epirubicin as neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer].
Chen CM; Shen KW; Liu GY; Wu J; Lu JS; Zhuang CJ; Han QX; Liu BL; Shao ZM; Shen ZZ
Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(11):745-7. PubMed ID: 16836921
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
18. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy in locally advanced breast cancer.
Singh G; Singh DP; Gupta D; Muralikrishna BV
J Surg Oncol; 1996 Jan; 61(1):38-41. PubMed ID: 8544458
[TBL] [Abstract][Full Text] [Related]
20. Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC).
Yan PW; Huang XE; Jiang Y; Tang JH; Xu HX; Xu X; Jin X
Asian Pac J Cancer Prev; 2010; 11(4):1115-8. PubMed ID: 21133634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
